Recently, many leaders in women's heath addressed with the FDA the black box warning on vaginal estrogen.
Vulvovaginal atrophy (VVA) is when your vaginal walls become inflamed, dry, and thin due to your body having less estrogen.
VVA causes significant medical issues for most women in menopause, including dryness, pain with intercourse, and bladder urgency.
It can contribute to pelvic prolapse and subsequent difficulty emptying the bladder and/or rectum, as well as incontinence.
Women deserve treatment options, and for many, vaginal estrogen provides a safe and effective option. The current FDA black box class warning causes confusion and undue concern by patients or health care providers reading the label.
Listen in as Diana Bitner, MD, discusses VVA and the important new labeling you need to know about vaginal estrogen.